ISSUED ON BEHALF OF BATTERY X METALS INC.

See How a Circular Economy and Battery X Metals Inc. (CSE:BATX) (OTC:BATXF) Are Key to Meeting the 670% Surge in Lithium-Ion Battery Demand^[1] and Driving Global Electrification

The global shift towards clean energy is driving up the need for lithium-ion batteries. This is mainly due to the rapid growth of electric vehicles (EVs) and new regulations and incentives like the U.S. Inflation Reduction Act and Europe’s “Fit for 55” plan. ^[2],^[3]

According to analysts at McKinsey & Company, by 2030, the demand for lithium-ion batteries is expected to rise by 670%.^[4]

Analysts at Benchmark have also predicted the global battery industry will need $514 billion to meet demand by 2030, and a whopping $920 billion by 2035.^[5]

All the while… the supply chain is clearly not ready for this increase.

Critical battery materials like lithium, nickel, cobalt, and graphite are each projected to be in short supply very soon.^[6]

On top of that, only about 5% of lithium-ion batteries are recycled today^[7], meaning valuable materials are being wasted.

Graphite is one of the highest sought-after resources, at the moment:

“Our batteries should be called nickel-graphite, because they’re mostly nickel & graphite” (Elon Musk, 2016)[8]

This highlights the urgent need for a green circular economy approach, where products and materials are reused, recycled, and put back in the supply chain for as long as possible to minimize waste and reduce reliance on raw material extraction.

Millions of EV batteries have either surpassed or are nearing the end of their warranties, with 3.4 million EV batteries expected to be removed from their original cars by 2025^[9].

Replacing these batteries can be very expensive ($4,000-$18,000)^[10], forcing owners to look for cheaper ways to  maintain or extend the life of their batteries^[11].

Battery replacement has risen to the top of potential EV buyers’ list of concerns of EV batteries[12].  BATX is focused on addressing this concern by developing technology that diagnoses the health and extends their lifespan.

Without new environmentally-friendly battery recycling, diagnosis, and longevity technology, the clean energy transition could face big challenges^[13].

This rising demand for battery materials and the need for sustainable solutions opens a unique opportunity for companies that can innovate in areas like battery recycling and lifespan extension.

 Meet Battery X Metals Inc. (CSE:BATX) (OTC:BATXF), a Forward-Thinking Company Revolutionizing the Lithium-Ion Battery Industry with Innovative Recycling, Health Diagnostics, and Lifespan Extension Technology.

Battery X Metals Inc. (CSE:BATX) (OTC:BATXF) is tackling one of the biggest challenges in the battery industry: sustainability.

As the markets for EVs and energy storage systems grow, the demand for affordable ways to recycle, diagnose, and extend battery life has never been greater.

With demand for EV batteries expected to skyrocket, BATX is positioned to benefit from this sustained growth.

BATX’s innovative recycling process recovers critical battery materials like graphite, lithium, nickel, cobalt, and graphite from used batteries.

Their proprietary technology reduces the need for new mining and introduces new technologies to support and enhance the circular economy by putting these metals back into the supply chain.

But recycling is only part of the solution.

Through its portfolio company, Lithium-ion Battery Renewable Technologies Inc. (“LIBRT”), BATX is driving innovation in battery lifespan extension. LIBRT’s proprietary battery diagnostics & rebalancing technology can spot issues in EV batteries early and help extend their life by rebalancing cells through its proprietary technology before they fail.

Regular checks and the rebalancing process (similar to an “oil change” for traditional ICE vehicles) can save EV owners money by delaying or avoiding costly replacements, and reduce battery waste.

With these innovative solutions, BATX is positioned as a leader in the clean energy shift, offering both environmental and economic benefits.

It also presents an exciting investment opportunity for those looking to support the future of sustainable energy.

Let’s now take a deeper look into why Battery X Metals Inc. (CSE:BATX) (OTC:BATXF) is a force to be reckoned with in the changing global economy.

---

7 Reasons
Investors Should Pay Attention to
Battery X Metals Inc.
(CSE:BATX) (OTC:BATXF)

1 – Proprietary Recycling Technology

BATX’s froth flotation process has the potential to be game-changer in battery recycling. This eco-friendly proprietary technology, being developed in partnership with a Global Top 20 university, aims to recover critical battery-grade materials like graphite, lithium, nickel, and cobalt, from used batteries. By reducing the need for new mining, it supports a circular economy and contributes to sustainable manufacturing.

2 – Advanced Diagnostic & Rebalancing Platform 

Through its subsidiary LIBRT, BATX has developed a proprietary diagnostic and rebalancing machine that extends the life of lithium-ion batteries. This innovative technology diagnoses battery health and actively rebalances cells to maximize battery lifespan, offering EV owners a cost-effective alternative to battery replacement.

3 – Strategic Lithium Exploration & Diversified Portfolio

BATX controls key lithium exploration projects in North America, including the Y Lithium Project and Nunavik Leaf River Project, and Abitibi Lithium Project. Additionally, BATX has diversified its portfolio by investing in precious metals projects, such as the Belanger Property and Premier Silver Corp.

4 – Key Partnerships

Its partnership with a Global Top 20 university further strengthens its leadership in developing innovative recycling technologies, and LIBRT’s partnership with BJPN accelerates the development of Prototype 2.0 of its proprietary diagnostic and rebalancing machine

5 – Aligned with Clean Energy Goals

BATX is directly contributing to global efforts like the U.S. Inflation Reduction Act and Europe’s Fit for 55 plan by focusing on reducing waste and improving battery lifespan. These efforts align with long-term sustainability goals, positioning BATX as a critical player in the clean energy transition.

6 – Emerging Leader in the Circular Economy

By recovering and reintroducing critical metals and graphite back into the battery supply chain, BATX is driving a closed-loop system that significantly reduces environmental impact and production costs, supporting both sustainable energy and economic growth.

7 – Poised for Long-Term Growth

With global demand for lithium-ion batteries expected to increase by 670% by 2030^[14], BATX is well-positioned to benefit from the surging EV and energy storage markets. This growing demand creates significant long-term opportunities for BATX’s innovative technologies and exploration efforts.

---

---

---

Froth Flotation Process: Pioneering Battery Recycling

At the core of Battery X Metals Inc.’s (CSE:BATX) (OTC:BATXF) strategy is its proprietary froth flotation process, an innovative technology optimized for recovering valuable metals from black mass—the shredded remains of lithium-ion batteries.

This process efficiently recovers critical materials like lithium, nickel, cobalt and graphite from used batteries, reducing the need for new mining operations and conserving natural resources. The BATX process is cleaner, eco-friendly, and cost-effective. It avoids burning Black Mass and using chemicals, reducing pollution risks.

Benefits of the froth flotation process:

• Supports a circular economy by reintroducing recycled battery materials into the supply chain.
• Lowers environmental impact by minimizing waste and resource extraction.
• Aims to create economic savings for manufacturers and consumers alike.

---

LIBRT’s Proprietary Diagnostic and Rebalancing Technology

Battery X Metals Inc. (CSE:BATX) (OTC:BATXF) is also positioning itself at the forefront of sustainable battery innovation through its 49%-owned portfolio company, Li-ion Battery Renewable Technologies Inc. (LIBRT).

LIBRT has developed a proprietary system designed to diagnose and effectively renew EV batteries offering a cost-effective and environmentally friendly solution to the growing problem of battery degradation.

As analysts project more than 12 million tons of lithium-ion batteries will no longer work in EVs by 2030^[15], with 3.4 million EV batteries expected to be removed from their original cars by 2025^[16], LIBRT’s technology provides a much-needed alternative to costly replacements.

Instead of disposing of aging batteries, LIBRT’s innovative solution helps rebalancing them and restoring them to optimal performance, extending their lifespan and contributing to a more sustainable approach to electric transportation.

Key Features of LIBRT’s Technology:

• Battery Diagnostics: LIBRT’s system assesses the health of each battery cell, identifying early signs of degradation. By detecting issues like imbalances in voltage or temperature, the system ensures EV batteries remain safe and reliable for longer.
• Cell Rebalancing: Using proprietary technology, LIBRT rebalances the charge and voltage across all cells within the battery pack, improving overall performance, safety, and ensuring that every cell is working efficiently, by keeping them all at the same level of capacity.
• Prototype 2.0 Development: The latest advancements in LIBRT’s technology, including Prototype 2.0, further enhance diagnostics by improving the accuracy of State of Health (SOH) and State of Charge (SOC) assessments, as well as optimizing the rebalancing process.

LIBRT’s collaboration with key partners, in North America and internationally, is driving the development and future commercialization of this technology, moving it closer to widespread deployment in both the EV market and Battery Energy Storage Systems (BESS).

With its ability to prolong battery life, LIBRT’s solution offers significant cost savings for EV owners, while supporting global sustainability efforts by reducing waste and minimizing the environmental impact of battery disposal.

Together, these innovations are helping LIBRT position itself as a leader in the battery diagnostics and battery longevity space, offering long-term benefits for consumers, manufacturers, service centers, recyclers and the clean energy sector as a whole.

---

---

Strategic Mineral Exploration

As the demand for lithium-ion batteries continues to rise, securing a stable supply of critical battery metals is becoming increasingly important.

Battery X Metals Inc. (CSE:BATX) (OTC:BATXF) is taking proactive steps to address this challenge through several strategic exploration projects across North America, aimed at ensuring a domestic supply of key materials like lithium, nickel, cobalt and graphite.

One of the company’s flagship initiatives is the Y Lithium Project in Northern Saskatchewan. This project is strategically positioned to reduce North America’s dependency on foreign lithium sources—a metal essential for producing EV batteries.

The Y Lithium Project is poised to provide a reliable and sustainable supply of lithium to meet the growing demand from the electric vehicle and energy storage industries.

Additionally, BATX holds the Nunavik Project and the Abitibi Lithium Hub, which further diversify their supply of critical battery metals. These projects are crucial for supporting the North American clean energy market and addressing the looming shortages of critical materials that are essential for battery production.

Beyond battery metals, BATX is also involved in precious metal exploration through its Belanger Gold-Copper Project and its stake in Premier Silver Corp, which is  a shareholder of the Malley Mine, in Peru, adding diversification to its portfolio and increasing its market resilience.

By focusing on domestic exploration, BATX is strengthening the North American battery supply chain, reducing both environmental and economic risks associated with relying on foreign imports.

Through its exploration efforts, BATX ensures the future of clean energy remains secure, sustainable, and aligned with North America’s energy independence goals.

---

Key Research Alliances

Battery X Metals Inc. (CSE:BATX) (OTC:BATXF) is advancing its proprietary battery recycling technology through strategic partnerships, including a standout collaboration with a Global Top 20 university.

This academic partnership plays a vital role in the development of BATX’s proprietary froth flotation process, which efficiently recovers critical battery materials like lithium, nickel, graphite and cobalt from used batteries. By working closely with world-class researchers, BATX continues to refine this cutting-edge technology, enhancing the sustainability of its recycling operations.

Beyond recycling, as mentioned above, BATX is also driving innovation in battery diagnostics and rebalancing technology through LIBRT’s collaboration with BJPN, a lab, specialized in developing advanced technologies. This partnership accelerates the development and commercialization of Prototype 2.0, strengthening BATX’s capacity to extend battery lifespans and improve the performance of Battery Energy Storage Systems (BESS).

By collaborating with both academic and industry leaders, BATX ensures its solutions are backed by rigorous research and cutting-edge advancements, solidifying its position as a leader in battery recycling and sustainability innovations.

---

---

Strong Management

In order to achieve its goals, Battery X Metals Inc. (CSE:BATX) (OTC:BATXF)  is led by a skilled team with diverse backgrounds in strategic business development, finance, clean energy technologies, corporate leadership, and geology, positioning the company at the forefront of sustainable energy solutions.

BATX’s leadership team includes:

 

---

BEFORE YOU GO…

Battery X Metals Inc. (CSE:BATX) (OTC:BATXF) is on the brink of transformative growth, driven by its innovative battery recycling technology and strategic critical mineral exploration efforts—both of which are integral to the future of clean energy.

As the world shifts towards sustainable energy storage, BATX is playing a pivotal role, with technologies designed to extend the life of batteries and reduce environmental impact.

With upcoming developments in diagnostics and recycling, 2024-25 is shaping up to be a defining year for the company.

Stay informed on BATX’s latest milestones and exciting advancements—subscribe now to receive updates directly.

Visit the official Battery X Metals website to learn more and follow their journey towards a greener future.

---

---

USA News Group
Editorial Staff

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Battery X Metals Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Battery X Metals Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Battery X Metals Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares Battery X Metals Inc. at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of Battery X Metals Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

---

SOURCES CITED:

^[1] https://www.mckinsey.com/industries/automotive-and-assembly/our-insights/battery-2030-resilient-sustainable-and-circular

^[2] https://www.irs.gov/credits-deductions/credits-for-new-clean-vehicles-purchased-in-2023-or-after#:~:text=Who%20qualifies,purchased%20from%202023%20to%202032.

^[3] https://climate.ec.europa.eu/news-your-voice/news/fit-55-eu-reaches-new-milestone-make-all-new-cars-and-vans-zero-emission-2035-2023-03-28_en

^[4] https://www.mckinsey.com/industries/automotive-and-assembly/our-insights/battery-2030-resilient-sustainable-and-circular

^[5] https://source.benchmarkminerals.com/article/financing-the-battery-arms-race-the-514-billion-cost-of-bridging-the-global-ev-supply-chain-divide?utm_medium=email&_hsmi=73031805&utm_content=73031805&utm_source=hs_email

^[6] https://www.iea.org/reports/global-critical-minerals-outlook-2024/executive-summary

^[7] https://www.cas.org/resources/cas-insights/lithium-ion-battery-recycling

[8] https://www.gsixenergy.com/media/elon-musks-nickel-graphite-revelation-our-batteries-should-be-called-nickel-graphite-highlights-the-crucial-role-of-graphite-in-ev-batteries#:~:text=Elon%20Musk%3A%20%22Our%20Batteries%20Should,of%20Graphite%20in%20EV%20Batteries&text=In%20an%20interview%2C%20Elon%20Musk,(EVs)%20and%20battery%20technology.

^[9] https://www.kbb.com/car-news/where-will-ev-batteries-go-when-were-done-with-them/

^[10] https://www.consumeraffairs.com/automotive/ev-battery-replacement-cost.html

^[11] https://www.kiavictoria.ca/seven-biggest-mistakes-people-make-with-their-ev-battery-that-will-cost-you/

[12] https://www.ey.com/en_us/newsroom/2024/09/us-consumers-less-likely-to-purchase-an-ev-than-last-year

^[13] https://www.weforum.org/agenda/2024/02/battery-storage-solutions-clean-energy-transition/#:~:text=Energy%20consumption%20and%20production%20contribute,the%20slowest%20rate%20since%202010.

^[14] https://www.mckinsey.com/industries/automotive-and-assembly/our-insights/battery-2030-resilient-sustainable-and-circular

^[15] https://www.batterycycle.io/replacing-your-ev-battery-when-it-reaches-its-end-of-life/#:~:text=According%20to%20some%20estimates%2C%20there,duty%20ICE%20vehicles%20from%202030.

^[16] https://www.kbb.com/car-news/where-will-ev-batteries-go-when-were-done-with-them/

Worldwide Lithium Shortages Drive World-Class Project in Argentina Developed by Lithium South (TSXV:LIS) (OTC:LISMF)

 

A worldwide battle to secure tomorrow’s energy future is underway today, as countries everywhere race to get their hands on a limited supply of lithium.

Not only are analysts sounding the alarm because a worldwide shortage of the metal being predicted by 2025[1], but also that by 2030 lithium demand is set to reach 2.4 million tonnes LCE[2] — Lithium consumption has already nearly quadrupled since 2010[3], and it doesn’t look at all like that trend is going to change any time soon.[4]

Experts estimate that meeting this demand will require at least US$42 billion in new investment to accomplish[5], and that by 2028, the global lithium market is expected to reach US$8.2 billion.[6]

However, where and how that money is spent is still up in the air. Right now there are several critics who are concerned with how lithium is produced, and how sustainable the industry is as a whole.[7]

Located right next door to two major lithium operations in the renowned Lithium Triangle, Lithium South Development Corporation (TSXV:LIS) (OTC:LISMF) recently increased its Resource by 175% at its world-class project.

Newly published Preliminary Economic Assessment (PEA) showing a NPV (after tax) of nearly US$1Billion,[8] LIS is quickly moving from being a lithium explorer to a lithium developer.

With a current Market Cap. of Approx. US$23.5 million – Lithium South issues PEA showing US$938 million Net Present Value, LIS should demand everyone’s attention.

Link to announcement: https://www.lithiumsouth.com/posts/preliminary-economic-assessment-filed-on-sedar/

 

With a PEA in place with a financial model that shows a Net Present Value (NPV) after tax of US$938 million, an after-tax internal Rate of Return of 31.6% and a 2.5-year payback, and with a production well already installed and pumping on site at the Alba Sabrina claim block and additional wells planned for the Norma Edith and Viamonte claim blocks on the project[9], Lithium South is processing test work, and pilot plant construction that would allow the HMN Li Project to have a Feasibility Study in early this year (2024).

Now equipped with a newly signed Cooperative Development Agreement with South Korean industry giant POSCO, they will have support through jointly developing two of the HMN Li Project’s most promising claim blocks.[10]

Let’s now take a deeper look into why Lithium South Development (TSXV:LIS) (OTC:LISMF) is in a great position to become one of the world’s next big lithium producers in the not-so-distant future…

8 Reasons Why Lithium South Development Corporation (TSXV:LIS) (OTC:LISMF) is Primed to Become a Major Player in the Lithium Industry

 

1. Top-Notch Real Estate: The 100%-owned HMN Li Project is located in Salta Province spanning a package of 5,687 hectares located directly adjacent to a $4-billion project developed by POSCO (who has signed a Cooperative Development Agreement to jointly develop HMN Li brines). The project comes with good weather, an ideal location for evaporation extraction, a potentially sustainable water source, a gas pipeline near the property, and environmental permitting that is nearing completion.
2. The Lithium M&A Market is still HOT: Recent Acquisitions in the lithium space have been going for between US$227-962 million, meaning valuations are on the rise.[11]^,[12]^,[13]^, [14]^,[15]^,[16]
3. Successful Resource Expansion Track Record: Thanks to a recent drill program, Lithium South succeeded in expanding the LCE resource on the HMN Li Project by 175% to a 1.57 million tonnes lithium carbonate equivalent[17], with 90% of the resource in the Measured category (the highest resource category).
4. Pilot Plant and Pumping Wells Underway: A well drilling campaign is already underway for pumping/production wells to establish well flow. Evaporation test work is underway to validate this low-cost option. Due to the quality of the brine, recovery rates are anticipated to approach 70% (subject to QP certification) which would be high for this recovery method.[18]
5. New ~US$1B PEA and Upcoming Feasibility Study: Once the pumping tests are completed, results will be provided for analysis to deliver key information for the upcoming Feasibility Study which is expected in early 2024. In April, Lithium South filed its PEA,[19] titled N.I. 43-101 Preliminary Economic Assessment Hombre Muerto North Lithium Project, Salta, Argentina, in which the financial model shows a NPV (after tax) of US$938 million and a 2.5-year payback.
6. Potential Revaluation Possibilities: With recent consolidation on the salar, Lithium South has Galan, POSCO, and the new Livent/Allkem merger entity as its neighbors, and with POSCO spending US$4B to develop their lithium production directly adjacent to LIS’s claim package, the company could potentially be revalued in relation to its peers.
7. Proven Extraction Possibilities: Lithium South is evaluating low risk, industry proven evaporation extraction for its HMN Li Project. A network of ponds has been constructed (https://www.lithiumsouth.com) to prove the process. And technical expertise has been brought on board to “optimize” the extraction process to increase recovery to potentially 70%.
8. Friends in High Places: Lithium South has recently signed a new cooperative development agreement with South Korean industry giant POSCO, representing a significant milestone in the development of HMN Li, including jointly developing two claim blocks on a 50/50 brine share basis, showcasing a spirit of partnership and pragmatism.

How Does Lithium South Development (TSXV:LIS) (OTC:LISMF) Stack Up With Its Neighbors?

Lithium South Development’s (TSXV:LIS) (OTC:LISMF)HMN Li Project is in great company, and surrounded by several major projects. Where the smart investor will now pay close attention is towards where the company is now, where it’s going, and how it will get there.

Lithium South has wasted no time in getting things ready, having already worked to greatly increase the project’s resource estimate, publish a PEA, and is now in the process of putting in a pilot plant and pumping wells.

As the project advances, it’s worth noting the more advanced projects nearby, and how their progress might be able to give a glimpse of where HMN Li may be headed.

THE POSCO FACTOR

To get an idea of scale, one can look no further than the nearby lithium brine operation of South Korean steelmaking giant POSCO, which in 2022 announced a significant investment of US$4 billion into their project in the same Salar de Hombre Muerto as Lithium South. In June 2023, POSCO made a US$800M investment into the project to move it closer to production[20] and in September 2023, pledged another US$1.7 billion investment in Argentina[21].

At the POSCO project (named Sal de Oro)[22], it’s anticipated to initially produce 25,000 tonnes of lithium hydroxide annually, before expanding up to 100,000 tonnes annually—and the company hopes to commence operations in early-to-mid 2024.[23]

Prior to POSCO paying US$280 million to Galaxy Resources to acquire the project, the previous owners had named the project Sal de Vida, and had put out an updated 2018 Feasibility Study[24], when lithium prices were half price compared to today. It provided the following highlights:

• NPV of US$1.48 billion at an 8% discount rate
• IRR of 26.9% with post-tax payback period of ~3 years from first production
• JORC-compliant reserve estimate of 1.1 million tonnes of recoverable lithium carbonate equivalent (“LCE”) to support a long initial project life with 25ktpa of lithium carbonate and 94ktpa of potash production respectively
• LCE Mineral Resource Estimate of 7.232 Mt LCE (M+Ind+Inf) at average grade of 753 mg/L or ppm
  • 565,000 tonnes LCE in Measured category
  • 119 Mt of potassium at 8,377 mg/L or ppm

Now although Lithium South is still in the process of preparing a Feasibility Study in 2024, in April 2024 the company put out a Preliminary Economic Assessment[25] (updating on the PEA put out in 2019)[26] and by piecing that together with recently updated mineral resource estimates[27], we get the following highlights:

• Post-Tax NPV of US$3.294B
• IRR of 31.6% with pay-back period of 2.5 years
• 5831 Mt LCE
  • 90% of resource in Measured category (~1.425Mt LCE)
  • Average grade 736 mg/L Li

 

Lithium South’s current updated PEA[28] used roughly the same price used in 2019 ($12,420 per tonne in 2024, compared to $12,400 used in 2019), determined using the historic three year trailing average price and the projected price for the next two years. Within the PEA is a financial model that shows a Net Present Value (NPV) after tax of US$938 million, an after-tax internal Rate of Return of 31.6%, and a 2.5-year payback. Now the company is preparing for a Feasibility Study that is expected to be delivered later this year.

So far in 2024, the proximity of the HMN Li Project to POSCO has become even closer. Because both Lithium South’s and POSCO’s assets hold claims to the same ground but in different Argentinian provinces, the two have come to a Cooperative Development Agreement to jointly develop two prominent HMN Li claim blocks on a 50/50 brine share basis.

This collaboration signifies a strategic advancement, particularly in the development of the Norma Edit and Viamonte claim blocks. Addressing historical provincial title issues, this partnership is key to tapping into the latent potential of these areas. With POSCO’s involvement, known for its robust presence in the lithium and steel industries, Lithium South fortifies its position in the market, underscoring its commitment to sustainable energy solutions.

WHEN TECPETROL WENT ALL IN ON ALLI

Another nearby property that’s worth consideration is that of Alpha Lithium and its Tolillar property which was developed and grown to its present state of a respectable mineral resource of 2.1 Mt LCE Indicated and another 1.2 Mt LCE Inferred.

The project’s potential garnered enough attention to entice Tecpetrol (a subsidiary of the Techint Group) to offer a premium all-cash proposal to acquire Alpha Lithium for a whopping C$273M (~US$199M)[29]. The deal was approved and finalized before the end of 2023[30].

WHAT DOES THIS POTENTIALLY MEAN FOR LIS?

Even if Lithium South Development (TSXV:LIS) (OTC:LISMF) doesn’t take the project all the way to production on its own, it’s surrounded by stories of major takeout target successes.

According to the company’s calculations, the HMN Li Project is near the top tier in terms of grade and chemistry, meaning it not only has a high grade of lithium that’s ahead of several other big players and their massive projects, but also that it comes with a favourably low magnesium to lithium ratio.

As of January 10, 2024, some might say that Lithium South Development’s (TSXV:LIS) (OTC:LISMF) stock value is still undervalued—given that the company’s market cap is less than US$23M, with a PEA in hand that values the flagship project nearly 40X that amount at US$938 million, and being surrounded by nearby projects that were acquired and sold for upwards of 9 digits each.

The relevance of Lithium South’s high lithium grades cannot be overstated.

Even if we’re looking at conventional brine evaporation ponds, lithium grade effects the size of the ponds. The higher the grade the smaller the pond. Pond size accounts for nearly 50% of the CAPEX of a brine project.

Meaning, the higher the grade, the lower the CAPEX.

Where does Lithium South’s HMN Li stack up amongst its peers?

It’s worth putting the HMN Li project together with peers, and to use our own discretion in deciding if the current valuation for Lithium South is fair or not.

Below is a table of peers with similar promising lithium projects:

Company	Symbol	Share Price (USD)	Mkt Cap (USD)	Primary Lithium Assets
Lithium South Development	TSXV:LIS OTC:LISMF	$0.21	$22.6M	HMN Li 1.58Mt LCE @ 736 mg/L Li
Argentina Lithium & Energy Corp.	TSXV:LIT OTC:LILIF	$0.13	$18.7M	Rincon West Antofalla North Pocitos Incahuasi   (NO RESOURCE CALCULATION TO DATE)
Galan Lithium	OTC:GLNLF	$0.12	$61.9M	Hombre Muerto West and Candelas 7.3Mt LCE @ 852 mg/L Li[31]
POSCO Holdings	NYSE:PKX	$69.49	$21.1B	Sol de Oro 7.2Mt LCE @ 753 mg/L Li

*share price and market cap taken from Yahoo! Finance on July 15, 2024

Strong Leadership Team

In order to properly assess and work with a potentially game-changing technology in one of the world’s top lithium production regions, the HMN Li project requires capable hands… Thankfully, Lithium South Development (TSXV:LIS) (OTC:LISMF) is in VERY capable hands.

LIS’s leadership team includes:

Adrian F. C. Hobkirk – President and CEO: Hobkirk has 32 years of experience in the mining and venture capital industry, including extensive experience working in Argentina. He is the co-discoverer of the Dublin Gulch Gold Deposit (Yukon) and the Yarnell Gold Mine (Arizona). He’s explored for precious metals around the world, with LIS being his first venture into lithium. Hobkirk is the founder of Lithium South Development Corp., having acquired the HMN Lithium Project and managed its development to date. 

Christopher P. Cherry – CFO and Director: Cherry has over 20 years of corporate accounting and audit experience. Formerly an auditor with KPMG, he has extensive corporate experience and has held senior-level positions for several public mining companies. Cherry is a certified general accountant and a chartered accountant.

Yi Hua Dai, PhD – Director: Yi Hua (PhD) founded Chemphys in 1998 to focus on battery quality and high purity lithium processing. He’s a certified Technical and Economic Expert of Sichuan Province and China Non-ferrous Metals Industry Association Expert. He has a proven record of leading the development of lithium manufacturing techniques with 24 patents valid and under application.

Alison Dai – Director: Dai has 9 years of experience in the lithium industry and is responsible for business development and is a director for Chengdu Chemphys Chemical Industry Co., Ltd. In her role at Chemphys, Dai has been involved in developing strategic partnerships, international markets and procurement. Prior to joining Chemphys, Dai was an investment banking analyst at J.P. Morgan Australia in the mining and metals team.

Fernando E. Villarroel – VP & Director Project Development: Villarroel has 12 years of experience in the mining industry in Argentina with a focus on Lithium process development. From 2009 to 2013 he worked with Lithium Americas Corp. (Minera Exar S.A.) as Project Manager which included construction management and commissioning of the initial pilot evaporation facilities and laboratory at the Cauchari Olaroz Lithium Project. He has also acted as a consultant to Neo Lithium and International Lithium Inc. He holds a degree in Industrial Engineering and has specialized training in Data Modeling & Analysis for Business and Engineering from M.I.T.

Vijay Mehta, PhD. – Technical Consultant and Qualified Person: A recognized expert in lithium mining and processing, Dr. Mehta (PhD) brings almost five decades of experience to LIS. His experience includes evaluating the technological and economic feasibility of lithium brine projects around the world. He was the Product and Process Technology Development Leader of FMC Corporation for 30 years and was one of the founding developers of FMC’s lithium plant at the Hombre Muerto Salar, Argentina, which has been in production since 1998. He holds 12 lithium related U.S. patents and has published over 50 technology reports and ten academic papers.

8 Reasons to Put Lithium South Development (TSXV:LIS) (OTC:LISMF) on Your Must-Watch List:

 

1  Top-Notch Real Estate

2  The Lithium M&A Market is HOT

3  Successful Resource Expansion Track Record

4  Pilot Plant and Pumping Wells Underway

5  New PEA with Upcoming Feasibility Study

6  Potential Revaluation

7  Extraction Possibilities

8  Cooperative Development Agreement with POSCO

 

BEFORE YOU GO!

Now that you’ve digested the fruits of our research, it’s time to follow up with some research of your own.

NOW IS THE PERFECT TIME for smart investors to seriously follow the rapidly evolving Lithium South Development (TSXV:LIS) (OTC:LISMF) story.

LIS recently successfully expanded its already impressive resource in one of the world’s most sought after lithium jurisdictions, and put out a new PEA showing a NPV of nearly US$1B. Other lithium assets in the region are being acquired at premium prices, and send a signal that Lithium South could very well be holding a highly-sought-after asset of its own in the very near future.

So, do your own due diligence, and don’t forget to click here to sign up for the Lithium South’s newsletter to make sure you don’t miss out on any news and milestones along the way to becoming the next darling of the lithium sector.

Mr. William Feyerabend, a Consulting Geologist and Qualified Person under NI 43-101, participated in the production of this advertisement and approves of the technical an scientific disclosure contained herein.

USA News Group
Editorial Staff

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Lithium South Development Corporation advertising and digital media from the company directly. There may be 3rd parties who may have shares of Lithium South Development Corporation, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Lithium South Development Corporation which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares Lithium South Development Corporation at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of Lithium South Development Corporation and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

---

---

SOURCES CITED

[1] https://www.cnbc.com/2023/08/29/a-worldwide-lithium-shortage-could-come-as-soon-as-2025.html

[2] https://www.mining.com/global-lithium-production-hits-record-high-on-electric-vehicle-demand/

[3] https://elements.visualcapitalist.com/lithium-consumption-has-nearly-quadrupled-since-2010/

[4] https://www.fastmarkets.com/insights/lithium-demand-to-remain-unchanged/

[5] https://www.mining.com/web/lithium-sector-needs-42bn-as-pivot-from-china-adds-costs/

[6] https://www.globenewswire.com/en/news-release/2022/03/11/2401706/29442/en/Global-Lithium-Market-Expected-to-Reach-8-2-Billion-by-2028-Grand-View-Research-Inc.html

[7] https://www.investopedia.com/investing/lithium-mining-dirty-investment-or-sustainable-business/

[8] https://finance.yahoo.com/news/lithium-south-development-corporation-preliminary-120000815.html

[9] https://finance.yahoo.com/news/lithium-south-expands-production-well-120000158.html

[10] https://www.prnewswire.com/news-releases/lithium-south-announces-cooperative-development-agreement-with-posco-argentina-sau-on-hmn-li-project-302031863.html

[11] https://cassels.com/rep_work/lithium-americas-acquires-millennial-lithium-for-491-million/#:~:text=On%20January%2025%2C%202022%2C%20Lithium,)%2C%20for%20approximately%20%24491%20million

[12] https://www.torys.com/en/work/2021/10/ac32c619-adf6-4296-948e-c715f7cd7e55

[13] https://www.riotinto.com/news/releases/2022/Rio-Tinto-completes-acquisition-of-Rincon-lithium-project

[14] https://www.reuters.com/markets/deals/chinas-ganfeng-lithium-buy-lithea-inc-962-mln-2022-07-11/

[15] https://www.spglobal.com/marketintelligence/en/news-insights/trending/BMkeaW0fipj15tymy_shQg2

[16] https://www.mining-technology.com/news/lithium-americas-purchase-arena/#:~:text=Lithium%20Americas%20has%20concluded%20the,the%20business%20at%20%24227m

[17] https://finance.yahoo.com/news/175-increase-lithium-120000123.html

[18] https://www.lithiumsouth.com/projects/

[19] https://finance.yahoo.com/news/preliminary-economic-assessment-filed-sedar-120000767.html

[20] https://thedalesreport.com/trends/south-korean-mining-giant-posco-to-invest-800m-in-its-sal-de-oro-lithium-project-in-argentina/

[21] https://en.mercopress.com/2023/09/04/posco-pledges-us-1.7-bn-investment-in-argentina

[22] http://www.poscoargentina.com/en

[23] https://smallcaps.com.au/posco-invests-developing-project-world-renowned-lithium-triangle/

[24] https://www.miningdataonline.com/reports/Sal_de_Vida_FS_2018.pdf

[25] https://finance.yahoo.com/news/preliminary-economic-assessment-filed-sedar-120000767.html

[26] https://www.lithiumsouth.com/wp-content/uploads/HMN-Final-Report-190808.pdf

[27] https://finance.yahoo.com/news/175-increase-lithium-120000425.html

[28] https://www.lithiumsouth.com/wp-content/uploads/HMN-Final-Report-190808.pdf

[29] https://www.prnewswire.com/news-releases/tecpetrol-urges-alpha-lithium-shareholders-to-tender-as-soon-as-possible-following-positive-recommendation-by-the-alpha-board-of-directors-ahead-of-bid-deadline-of-3-october-2023-301942623.html

[30] https://www.globenewswire.com/news-release/2023/12/15/2796802/0/en/Alpha-Lithium-Shareholders-Approve-the-Privatization-of-Alpha-Lithium-by-Tecpetrol.html

[31] https://galanlithium.com.au/august-2023-diggers-and-dealers-presentation/

 

Issued on behalf of Oncolytics Biotech Inc.

With Phase 2 clinical results showing an estimated 76% survival improvement in HR+/HER2- metastatic breast cancer and a pancreatic cancer study cohort funded by PanCAN, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is capturing attention with a $4.79 price target[1]—an over 487% upside from its current valuation!

---

Cancer—a word that strikes fear into the hearts of many. Yet a revolution in how this formidable foe is fought is unfolding.

In recent years, cancer rates among younger generations—particularly Generation X and millennials—have risen sharply, rewriting our understanding of health in modern society. [2]  A complex web of lifestyle changes[3], environmental shifts[4], and genetic predispositions[5]  has fueled this troubling trend. The result? A growing burden on families, healthcare systems, and economies worldwide.

The stakes have never been higher. The global economic cost of cancer is projected to exceed $25 trillion over the next three decades[6]. Traditional treatments like chemotherapy and radiation, while life-saving for millions, are reaching their limits, leaving patients and physicians alike searching for more effective and less taxing options.

The demand for innovative solutions has created a booming market:

• The global cancer therapeutics market is expected to grow from $98.9 billion in 2018 to $180.2 billion by 2026 at a 7.7% CAGR. [7]
• The breast cancer drug market alone is projected to reach $55.9 billion by 2030, growing at an 8.2% CAGR. [8]
• Pancreatic cancer treatments, one of the most challenging areas in oncology, are anticipated to expand at a 4% CAGR, reaching $10.2 billion by 2034. [9]

Big Pharma has taken notice. Companies like Roche, AstraZeneca, and Pfizer are investing billions in partnerships and acquisitions, signaling a shift toward targeted immunotherapies and next-generation approaches. These companies know the future of cancer treatment isn’t just about attacking tumors—it’s about empowering the body’s own defenses to fight back. [10]^{,[11],[12],[13],[14],[15]}

Imagine treatments that don’t just kill cancer cells but teach the immune system how to prevent them from coming back. This isn’t a distant dream; it’s happening now. A new wave of therapies is poised to transform the way cancer is fought.

But among the countless innovations in oncology, one therapy is capturing the attention of scientists, physicians, and analysts alike—a groundbreaking approach that could redefine cancer care as we know it.

Enter pelareorep—a groundbreaking therapy that could one day redefine cancer treatment as we know it.

This innovative immunotherapy is making waves in the medical community by leveraging the body’s immune system to target and destroy cancer cells.

Recent trials have shown promising results, with significant clinical benefits, including improvements in survival rates for patients with some of the most challenging cancers.[16],[17],[18]

The driving force behind this revolutionary treatment is Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), a pioneering company at the forefront of immunotherapy innovation.

Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC)

With a commitment to improving the quality of life for cancer patients, Oncolytics is harnessing the potential of pelareorep to unlock the body’s antitumor capabilities.

In clinical studies, pelareorep has demonstrated remarkable success, particularly in metastatic breast cancer and pancreatic cancer. Patients treated with pelareorep and standard chemotherapy in the BRACELET-1 trial saw a 76% estimated improvement in overall survival, while the GOBLET trial showed a 62% objective response rate in pancreatic cancer. These breakthroughs have not gone unnoticed.

Backed by collaborations with industry giants like Roche, Pfizer, and Merck, as well as funding from the Pancreatic Cancer Action Network (PanCAN), Oncolytics is advancing pelareorep to late-stage clinical trials. With both breast cancer and pancreatic cancer receiving FDA Fast Track Designation, the path to regulatory approval is being accelerated, offering new hope to millions of patients worldwide.

But how does this innovative treatment work? And what does it mean for the future of cancer care? Stay tuned as we delve deeper into the science behind pelareorep and its potential to transform cancer treatment.

---

The Top 7 Reasons
Oncolytics Biotech Inc.
(NASDAQ:ONCY) (TSX:ONC)
is a Name to Watch in Biotech

1 Regulatory Triumphs: Oncolytics Biotech is making significant strides with TWO FDA Fast Track Designations [19]^,[20] for pelareorep in metastatic breast and pancreatic cancer. This designation allows for greater collaboration with the FDA in addition to potential expedited review and approval as Oncolytics prepares for a pivotal trial in HR+/HER2- metastatic breast cancer in 2025[21].

2 Strategic Alliances: Oncolytics is collaborating with industry leaders like Pfizer, Roche, and Merck, [22]  and has secured funding from the Pancreatic Cancer Action Network (PanCAN) to advance its pancreatic cancer program. These alliances enhance pelareorep’s development across multiple indications and validate its promise.

3 Clinical Breakthroughs: In recent trials, pelareorep demonstrated a 76% estimated improvement in overall survival (OS) for metastatic breast cancer patients in combination with chemotherapy (32.1 months vs. 18.2 months) [23]. Additionally, in pancreatic cancer, the GOBLET trial revealed a promising 62% objective response rate (ORR) when combined with checkpoint inhibitor monotherapy, and was recently given regulatory approval to continue patient enrollment into Cohort 5 of the study, which evaluates pelareorep with modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®)[24].

4 Market Expansion: With the global oncology market projected to grow to $180.2 billion by 2026 (7.7% CAGR) [25], and breast and pancreatic cancer treatments poised for significant expansion, Oncolytics is positioned to capture substantial market share with its innovative immunotherapeutic agent.

5 Expert Leadership: Led by a team of seasoned professionals, Oncolytics Biotech boasts decades of experience in drug development and commercialization. Their expertise is guiding the company through pivotal clinical milestones and strategic growth.

6 Robust Financial Health: With a cash position of $19.6 million, Oncolytics is well-equipped to fund ongoing research and key milestones into 2025, including additional data readouts and what is believes is a clear pathway to future commercialization opportunities. [26]

7 Commitment to Innovation: Oncolytics remains steadfast in its mission to advance cancer research. By turning “cold” tumors into “hot” ones that respond better to treatment, pelareorep is addressing critical gaps in cancer immunotherapy.

---

---

WHAT Analysts Are Saying + WHY the Market Is Slow to Catch On

Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is currently trading at $0.82, but analysts project a 1-year price target of $4.79, reflecting a potential upside of over 4870%. According to Yahoo! Finance (as of January 17, 2025)[27], Oncolytics boasts 8 Buy ratings, including 5 Strong Buys, underscoring strong confidence in the company’s future.

Despite the company’s remarkable Phase 2 BRACELET-1 results, which showed a 76% estimated improvement in overall survival for metastatic breast cancer patients, the market has been slow to respond. Why?

Historically, smaller biotech companies often see delayed stock reactions to groundbreaking data. It’s not uncommon for the big jumps in share price to come after pivotal milestones like:

• Regulatory approvals
• Key Phase 3 trial data
• Partnership announcements with major pharmaceutical players

For Oncolytics, the stage is set for significant catalysts like these in the future. With preparations underway for a registration-enabling study in metastatic breast cancer and advancements in its pancreatic cancer program supported by PanCAN funding, the pieces are falling into place.

This lag in market reaction creates a rare window for investors. The analysts see it. The data supports it. And the company’s momentum is building. The market hasn’t yet priced in the full potential of Oncolytics Biotech—and that’s where savvy investors can capitalize.

Don’t wait until the crowd catches on. Now is the time to act.

---

Pelareorep: Mechanism and Potential

Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is a trailblazer in cancer treatment, harnessing the power of the body’s immune system with pelareorep to target and eliminate cancer cells. This immunotherapeutic agent works by enhancing the effectiveness of chemotherapy and immunotherapy, transforming the tumor microenvironment to be more hostile to cancer.

How does it do this? Pelareorep transforms the tumor microenvironment by generating and recruiting immune cells to recognize and attack cancer. It enhances immune response by introducing double-stranded RNA into cancer cells, leading to inflammation and upregulation of PD-L1, which helps T-cells infiltrate and destroy the tumor.

This innovative approach allows pelareorep to work in harmony with chemotherapy, immune checkpoint inhibitors, and other therapies, boosting their effectiveness and offering hope for longer-lasting remissions.

Research and development efforts are in full swing, with key clinical trials like BRACELET-1 for breast cancer and GOBLET for pancreatic and anal cancer leading the charge​. These studies have shown impressive results, including significant improvements in objective response rate, progression-free survival, and overall survival rates​.

Pelareorep’s potential is expansive, offering hope across multiple cancer types by converting “cold” tumors into “hot” ones, making them more susceptible to attack from the immune system. It’s not just another cancer treatment—it’s a revolutionary approach to unleashing the full power of the immune system.

---

Transforming Breast Cancer Treatment

Breast cancer remains a formidable challenge, with over 310,000 new cases estimated to be diagnosed in the U.S. in 2024.[28] But with Oncolytics Biotech Inc.’s (NASDAQ:ONCY) (TSX:ONC) pelareorep, there’s new hope. It’s already showing big improvements for patients with HR+/HER2- metastatic breast cancer, especially those who have exhausted other treatment options.

With annual expenses reaching a total of $29.8 billion[29] for the total breast cancer market, HR+/HER2- metastatic breast cancer patients often face limited options once earlier-stage treatments like hormonal therapy or later-stage treatments like antibody-drug conjugates fail, leaving a significant unmet need in treatment​.[30]

Recently, Oncolytics reported favorable positive clinical results from its randomized Phase 2 study, BRACELET-1,[31] reinforcing their path towards a registration-enabling study as a result of constructive dialog with the FDA. [32]

A registration-enabling study is a pivotal clinical trial that is designed to provide the necessary data for a New Drug Application (NDA) submission to the FDA for approval.

Within the latest BRACELET-1 results, pelareorep (when combined with chemotherapy) helped patients go 12.1 months before their cancer got worse (median PFS)—almost double the time for patients on chemotherapy alone.[33]

Even better, the median overall survival (OS) could not be determined, as more than half of the patients were still alive at the study’s conclusion. However, estimates put OS at approximately 32 months compared to 18.2 months for chemotherapy alone​.

This data builds on the strong findings from the earlier IND-213 study, which also demonstrated a significant survival benefit when combining pelareorep with chemotherapy. Given this consistent success, Oncolytics Biotech is seemingly advancing pelareorep toward a registration-enabling trial[34].

FDA Process and Market Potential

Back in 2017, the FDA awarded pelareorep with Fast Track Designation for the treatment of metastatic breast cancer [35], providing a potential expedited regulatory review process and potential for accelerated approval.

How significant would a potential approval be?

The breast cancer drug market is poised for rapid growth, with projections from BioSpace showing it will grow from $32.93 billion in 2023 to $78.61 billion by 2033[36]. Additionally, DelveInsight predicts a 9.3% CAGR for the HR+/HER2- metastatic breast cancer market alone[37], underscoring the significant commercial opportunity for new treatments.

With promising results and regulatory momentum, pelareorep is poised to make a significant impact in the fight against breast cancer, offering new hope to patients worldwide.

---

Tackling Pancreatic Cancer

Pancreatic cancer. It’s known as the “silent killer,” and for a good reason. Each year, about 66,440 people in the U.S. are expected to be diagnosed[38], and it’s one of the deadliest cancers, with a five-year survival rate of just 13%​​.[39]

The symptoms are subtle, often going unnoticed until it’s too late, and the incidence rate among young women has skyrocketed by 208% over the past 30 years​.[40]

Enter pelareorep, a game-changing immunotherapy with the potential to turn the tide. In clinical trials, pelareorep has been making waves, especially when combined with treatments like chemotherapy and immune checkpoint inhibitors​.

Recent data from the GOBLET study revealed a remarkable 62% objective response rate,[41] more than doubling the results of historical control trials​.[42]

This promising progress hasn’t gone unnoticed. The Pancreatic Cancer Action Network (PanCAN) awarded Oncolytics Biotech a US$5 million Therapeutic Accelerator Award to support the continued development of pelareorep​.[43]

The FDA has also taken notice, granting pelareorep Fast Track Designation, which is designed to improve dialog with regulators and potentially accelerating its journey toward potential approval​.[44] In January, Germany’s medical regulatory body, the Paul-Ehrlich-Institute (PEI) approved  the continuation of patient enrollment into Cohort 5 of the GOBLET study. This cohort is evaluating pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq^®) in newly diagnosed pancreatic ductal adenocarcinoma (PDAC) patients.[45]

Backed by robust collaborations and cutting-edge science, pelareorep is not just making headlines—it’s potentially poised to set new standards in pancreatic cancer treatment. With each success, pelareorep is proving that the future of cancer treatment is nearly here, and it could be brighter than ever.

---

Advancing Solutions for Anal Cancer

The number of new anal cancer cases has been rising for many years, with a rise in incidence of 2.7% annually for the past decade in the USA[46]. The number of people who die from anal cancer each year has also been rising[47].

Contributing factors include HPV infection, lowered immunity, and smoking[48]​. There are treatment options for anal cancer, but they usually do not come cheaply.

In a 2018 study published in the Journal of Managed Care + Specialty Pharmacy, it was determined the average cost of the first 2 years of anal cancer treatment to be $127,531.[49]

The American Cancer Society estimates about 10,540 new cases of anal cancer in 2024 (3,360 in men, and 7,180 in women), with about 2,190 deaths (1,000 in men, and 1,190 in women). [50]

In response to this growing concern, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is positioning pelareorep towards the forefront of innovative treatment strategies. This cutting-edge therapy is being integrated into a combination therapy and is currently being tested in a clinical trial alongside an immune checkpoint inhibitor​.[51]

Recent trials have shown promising results, with pelareorep delivering positive interim data from the unresectable squamous cell carcinoma of the anal canal (SCCA) cohort of the Phase 2 GOBLET study, including a complete response in an indication where checkpoint inhibitor therapy alone has had limited success historically.[52] These results demonstrated an almost a 3X improvement compared to data from like studies evaluating checkpoint inhibitors in patients with more than one prior line of therapy.[53]^,[54],[55]

With the support of leading pharmaceutical companies and academic institutions, Oncolytics Biotech is advancing pelareorep through a strategic pathway toward potential regulatory approval​. The future implications are profound, offering a beacon of hope for more effective cancer care.

---

Financial Position and Market Overview

Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) stands on solid financial ground, boasting a cash position of $19.6 million (as of Sept. 30, 2024)[56], which provides a financial runway through key milestones well into 2025​.

The company’s share structure is designed to support its growth strategy, ensuring stability as Oncolytics continues to push the boundaries of immunotherapy.

AS MENTIONED ABOVE: Analysts consistently recognize Oncolytics’ strong market position and potential for substantial growth, with 4 analysts offering a consensus STRONG BUY rating​​.[57]

Recent strategic collaborations, such as the partnership with the Global Coalition for Adaptive Research (GCAR)[58] and funding from PanCAN,[59] underscore the company’s capability to secure critical resources and partnerships​​. These alliances not only bolster Oncolytics’ financial standing but also accelerate its path toward revolutionizing cancer treatment with pelareorep.

With a strategic financial framework and an innovative pipeline, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is poised for growth, paving the way for groundbreaking advancements in oncology.

---

ONCY Among Its Peers

Now let’s look at how Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) stacks up to its peers as a potential takeout target in the future by pharma giants looking for an oncology winner:

It’s clear that in the world of cancer treatment, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) stands out in this busy field.

---

MEET THE EXPERTS AT ONCOLYTICS BIOTECH

Developing a revolutionary treatment like pelareorep requires a powerhouse team, and Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) has just the right lineup to deliver. With experience from industry giants like Amgen, Bristol-Myers Squibb, and academic institutions such as Harvard Medical School, Oncolytics’ team is second to none.

Currently leading the charge is Wayne Pisano, Interim CEO and Chair of the Board, stepping in for Dr. Matt Coffey during his medical leave. Wayne Pisano is an industry veteran with over 30 years of experience in pharmaceuticals and 12 years in biotech.

Formerly the President and CEO of Sanofi Pasteur, he played a pivotal role in making it a leader in the global influenza vaccine market​.[60] Pisano’s interim leadership at Oncolytics ensures the company remains on track to achieve its strategic priorities and advance pelareorep through critical clinical milestones​.

Let’s meet some of them:

Matt Coffey, PhD, MBA – Co-Founder, Director, President & CEO
A leading expert in cancer virotherapy, Dr. Coffey has dedicated his career to studying how viruses can be harnessed to combat cancer. His groundbreaking research has been published in numerous prestigious scientific journals. Currently on medical leave, his vision continues to guide Oncolytics’ mission and strategy.

Patricia S. Andrews – Director
An accomplished biopharmaceutical executive, Pat Andrews brings extensive experience (including years with Pfizer) in navigating registrational trials and completing transformative business deals. Her strategic insights are instrumental as Oncolytics advances pelareorep toward pivotal studies.​

Thomas Heineman, MD, PhD – Head of Clinical Development and Operations
With over 25 years in drug development, Dr. Heineman has led numerous oncology projects, focusing on advancing treatments for cancers such as breast and pancreatic cancer.

Deborah M. Brown, B.Sc., MBA – Director
Known for her strategic leadership at EMD Serono and Accelera Canada, Deborah Brown is instrumental in guiding new medical businesses to success.

Bernd R. Seizinger, MD, PhD – Director
An expert in cancer drug discovery, Dr. Seizinger has served in top roles at Harvard Medical School and Princeton University, contributing to groundbreaking advancements in oncology.

Guided by these exceptional minds, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is paving the way for innovative cancer therapies that could change the lives of patients worldwide.

---

RECAP: 7 Things to Remember About
Oncolytics Biotech Inc.
(NASDAQ:ONCY) (TSX:ONC).

1.  Regulatory Triumphs

2.  Strategic Alliances

3.  Clinical Breakthroughs

4.  Market Expansion

5.  Expert Leadership

6.  Robust Financial Health

7.  Commitment to Innovation

---

Join the Revolution in Cancer Care

The fight against cancer is entering a transformative era, and Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is leading the charge. With pelareorep delivering breakthrough results in metastatic breast and pancreatic cancers, the potential to save and improve millions of lives is within reach.

Backed by visionary leadership, strategic partnerships with industry giants, and a strong financial position, Oncolytics is at the forefront of innovation in oncology. This is your chance to join a company that’s redefining cancer treatment with cutting-edge immunotherapy.

Whether you’re an investor, collaborator, or supporter, there’s a place for you in this groundbreaking journey. Together, we can push the boundaries of what’s possible in cancer care and bring hope to patients worldwide.

Stay informed and be part of the movement. Sign up for email alerts to receive the latest updates on Oncolytics Biotech’s progress, key milestones, and opportunities to get involved.

The future of oncology is here—don’t miss your chance to be a part of it.

 

USA News Group
Editorial Staff

---

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

---

SOURCES CITED:

[1] https://www.tipranks.com/stocks/oncy/forecast

[2] https://www.today.com/health/disease/cancer-rising-millennials-study-rcna164610

[3] https://www.cityofhope.org/whats-behind-rising-colorectal-cancer-rates-in-young-adults

[4] https://abcnews.go.com/Health/cancer-deaths-declining-troubling-increase-colon-breast-cancer/story?id=106427957

[5] https://edition.cnn.com/2024/07/31/health/millennials-gen-x-cancer-risk-study/index.html

[6] https://www.healio.com/news/hematology-oncology/20230223/global-economic-cost-of-cancer-estimated-to-exceed-25-trillion-over-30-years

[7] https://www.einnews.com/pr_news/728043865/cancer-therapeutics-market-exploring-global-investment-and-r-d-trends-cagr-7-7

[8] https://www.openpr.com/news/3596177/breast-cancer-drugs-market-size-share-trends-key-drivers

[9] https://www.openpr.com/news/3585977/at-a-cagr-of-12-4-pancreatic-cancer-treatment-market

[10] https://www.reuters.com/breakingviews/super-chemo-will-be-big-pharmas-next-tussle-2022-05-16/

[11] https://www.forbes.com/sites/greatspeculations/2019/07/10/was-the-47-billion-acquisition-of-genentech-in-2009-a-good-deal-for-roche/?sh=5c78818aa1aa

[12] https://www.fiercebiotech.com/biotech/eat-me-pfizer-swallows-cd47-biotech-trillium-2-3b-takeover

[13] https://www.wsj.com/business/ftc-settles-with-amgen-over-27-8-billion-deal-for-horizon-therapeutics-b96a2d69

[14] https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-announces-fda-approval-update

[15] https://www.fiercebiotech.com/biotech/sanofi-inks-2-5b-synthorx-takeover-to-gain-il-2-cancer-drug

[16] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-favorable-results-for-bracelet-1-breast-cancer-study-reinforcing-path-to-funding-of-a-registration-enabling-study/

[17] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-promising-pelareorep-data-in-pancreatic-and-anal-cancers-at-asco-gi-symposium/

[18] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-key-progress-and-upcoming-studies-for-breast-and-pancreatic-cancer-treatments-prepares-for-fda-accelerated-approval-path/

[19] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-receives-fda-fast-track-designation-for-the-treatment-of-advanced-metastatic-pancreatic-cancer/

[20] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-fda-fast-track-designation-for-reolysin-in-metastatic-breast-cancer/

[21] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-productive-fda-type-c-meeting-on-its-metastatic-breast-cancer-program/

[22] https://oncolyticsbiotech.com/pipeline/

[23] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-advances-toward-registration-enabling-trial-for-pelareorep-in-breast-cancer-with-submission-of-type-c-meeting-request-to-fda-2/

[24] https://finance.yahoo.com/news/regulatory-approval-clears-path-oncolytics-120000409.html

[25] https://www.einnews.com/pr_news/728043865/cancer-therapeutics-market-exploring-global-investment-and-r-d-trends-cagr-7-7

[26] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-third-quarter-financial-results-and-recent-operational-highlights-3/

[27] https://finance.yahoo.com/quote/ONCY/analysis/

[28] https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html

[29] https://www.cdc.gov/nccdphp/priorities/breast-cancer.html#:~:text=%2429.8%20billion%3A2-,Breast%20cancer%20has%20the%20highest%20treatment%20cost%20of%20any%20cancer,%243.5%20billion%20for%20prescription%20drugs.

[30] https://www.mdanderson.org/newsroom/sabcs-studies-suggest-novel-targeted-therapies-may-benefit-patients-metastatic-hr-plus-her2-breast-cancer.h00-159624168.html

[31] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-favorable-results-for-bracelet-1-breast-cancer-study-reinforcing-path-to-funding-of-a-registration-enabling-study/

[32] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-productive-fda-type-c-meeting-on-its-metastatic-breast-cancer-program/

[33] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-favorable-results-for-bracelet-1-breast-cancer-study-reinforcing-path-to-funding-of-a-registration-enabling-study/

[34] https://www.onclive.com/view/fda-receives-type-c-meeting-request-for-pelareorep-in-hr-her2-metastatic-breast-cancer

[35] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-fda-fast-track-designation-for-reolysin-in-metastatic-breast-cancer/

[36] https://www.biospace.com/breast-cancer-drugs-market-size-to-surpass-usd-78-61-bn-by-2033

[37] https://www.prnewswire.com/news-releases/metastatic-hrher2-breast-cancer-market-is-expected-to-showcase-a-significant-growth-at-a-cagr-of-9-3-by-2032–predicts-delveinsight-302004113.html

[38] https://www.cancer.org/cancer/types/pancreatic-cancer/about/key-statistics.html

[39] https://pancan.org/news/pancreatic-cancer-five-year-survival-rate-increases-to-13/

[40] https://www.dailymail.co.uk/health/article-13033795/Huge-spike-cancer-sparks-alarm-experts-baffled.html

[41] https://oncolyticsbiotech.com/press_releases/oncolytics-presents-positive-updated-pancreatic-cancer-data-from-goblet-phase-1-2-study-at-esmo/

[42] https://www.nejm.org/doi/full/10.1056/NEJMoa1304369

[43] https://pancan.org/news/pancans-5-million-therapeutic-accelerator-award-goes-to-oncolytics-biotech-inc/

[44] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-receives-fda-fast-track-designation-for-the-treatment-of-advanced-metastatic-pancreatic-cancer/

[45] https://finance.yahoo.com/news/regulatory-approval-clears-path-oncolytics-120000409.html

[46] https://pubmed.ncbi.nlm.nih.gov/31742639/

[47] https://seer.cancer.gov/statfacts/html/anus.html

[48] https://www.cancer.org/cancer/types/anal-cancer/causes-risks-prevention/what-causes.html

[49] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397580/

[50] https://www.cancer.org/cancer/types/anal-cancer/about/what-is-key-statistics.html

[51] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-initiates-enrollment-expansion-of-goblet-anal-cancer-cohort/

[52] https://oncolyticsbiotech.com/press_releases/oncolytics-announces-the-anal-cancer-cohort-of-the-goblet-phase-1-2-study-of-pelareorep-and-atezolizumab-has-met-the-success-criteria-for-efficacy/

[53] https://pubmed.ncbi.nlm.nih.gov/28453692/

[54] https://pubmed.ncbi.nlm.nih.gov/28223062/

[55] https://pubmed.ncbi.nlm.nih.gov/35816951/

[56] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-third-quarter-2024-financial-results-and-operational-highlights/

[57] https://www.tipranks.com/stocks/oncy/forecast

[58] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-preliminary-collaboration-with-gcar-for-inclusion-of-pelareorep-in-anticipated-pancreatic-cancer-trial/

[59] https://pancan.org/press-releases/the-pancreatic-cancer-action-network-selects-oncolytics-biotech-inc-to-receive-5-million-therapeutic-accelerator-award-to-develop-leading-edge-treatments/

[60] https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-president-and-chief-executive-officer-dr-matt-coffey-to-take-medical-leave-of-absence/